Promising data presented at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago indicated that adding a drug called durvalumab (brand name: Imfinzi) to the treatment plan for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback